Cromos Pharma, where the patients are

Bristol-Myers Squibb

Ambrx, BMS collaborate on next-gen antibody drug conjugates

Monday, May 6, 2013 10:09 AM

Ambrx, a clinical stage biopharmaceutical company, entered into a collaboration agreement with Bristol-Myers Squibb for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology.

More... »

CRF Health eCOA webinar series

David A. Dodd appointed president and CEO of Aeterna Zentaris

Friday, April 26, 2013 03:05 PM

Aeterna Zentaris, an oncology and endocrinology drug development company, has appointed David A. Dodd as president and CEO, succeeding Juergen Engel, PhD. Dodd has also been appointed director on the company's board of directors.

More... »


Merck, BMS to conduct phase II trial of MK-5172, daclatasvir for hep C

Monday, April 22, 2013 02:20 PM

Global healthcare company Merck has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of BMS’s investigational NS5A replication complex inhibitor, daclatasvir, and Merck's investigational NS3/4A protease inhibitor, MK-5172, for the treatment of chronic hepatitis C virus (HCV) infection, genotype 1.

More... »

Santaris Pharma, BMS form discovery alliance for RNA-targeted medicines

Wednesday, April 17, 2013 09:44 AM

Santaris Pharma, a privately held biopharmaceutical company focused on disease-related mRNAs and microRNAs, has formed a worldwide strategic alliance with Bristol-Myers Squibb to discover and develop novel medicines using Santaris Pharma's proprietary Locked Nucleic Acid (LNA) Drug Platform.

More... »

BMS selects Quintiles as preferred central laboratory provider

Tuesday, April 16, 2013 10:06 AM

Quintiles, a provider of biopharmaceutical development and commercial outsourcing services, has been chosen as a preferred provider by Bristol-Myers Squibb to provide global support for BMS's central lab work, biomarker testing and assay development for the next five years.

More... »

BMS to spend $250M to expand biologics facility, create 350 jobs

Friday, April 12, 2013 10:43 AM

Bristol-Myers Squibb (BMS) is planning a $250 million expansion of its large-scale biologics manufacturing facility in Devens, Mass. The expansion will introduce biologics development and clinical trial manufacturing capabilities to the site, while adding approximately 350 employees to the Devens workforce over time.

More... »

BMS appoints Francis Cuss as executive vice president, CSO

Monday, April 8, 2013 03:00 PM

Bristol-Myers Squibb, a global biopharmaceutical company, has appointed Francis Cuss, MB, BChir, FRCP, as executive vice president and chief scientific officer, effective July 1 after Elliott Sigal, M.D., Ph.D., retires.

More... »

LabCorp Clinical Trials selected as preferred provider by BMS

Monday, April 8, 2013 11:05 AM

Laboratory Corporation of America Holdings (LabCorp) announced that LabCorp Clinical Trials has been selected as a preferred provider for full-service global central laboratory services and biomarker testing by Bristol-Myers Squibb.

More... »

EntreMed announces changes to board of directors, CEO appointment

Friday, April 5, 2013 12:05 PM

The board of directors of EntreMed, a clinical-stage pharmaceutical company focused on cancer, has appointed two new individuals as directors. Joining the board are James Huang and Y. Alexander Wu, Ph.D.

More... »

New Jersey to hire displaced pharmaceutical workers

Wednesday, March 13, 2013 02:08 PM

New Jersey has announced a financial hiring incentive to employers through the state Department of Labor and Workforce Development (LWD) if they hire and train former pharmaceutical industry employees. Employers willing to hire displaced pharmaceutical workers may reduce the cost to train new employees under this new on-the-job training program, which will reimburse each employer up to between 50% and 90% of a new hire’s salary for up to six months and a maximum of $14,000

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs